Plain-English translation of NCT07767188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called obinutuzumab, given together with two standard lupus kidney medicines (mycophenolate mofetil and corticosteroids). The goal is to see if adding this new medication helps patients with active lupus nephritis—a serious condition where lupus attacks the kidneys—get better faster and more completely. Researchers want to understand if this combination is effective and safe as a first-line treatment.
Lupus nephritis is a severe form of lupus that can cause kidney damage and failure. While standard treatments help some patients, they don't work well enough for everyone. This trial is testing whether the medication can improve outcomes and help more patients avoid long-term kidney damage.
As a participant, you would receive the medication obinutuzumab added to your standard lupus kidney medicines at multiple research centers. You would attend regular clinic visits for blood tests, urine tests, and kidney function monitoring to track how well the treatment is working and check for any side effects. The study involves close follow-up to measure whether this combination approach helps control your lupus nephritis better than standard treatment alone.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China